- Trials with a EudraCT protocol (49)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
49 result(s) found for: Reverse transcription polymerase chain reaction.
Displaying page 1 of 3.
EudraCT Number: 2020-001224-33 | Sponsor Protocol Number: COV-HCQ | Start Date*: 2020-03-25 | |||||||||||
Sponsor Name:Universitätsklinikum Tübingen | |||||||||||||
Full Title: Randomized controlled trial of hydroxychloroquine versus placebo for the treatment of adult patients with acute coronavirus disease 2019 – COVID-19 | |||||||||||||
Medical condition: Acute coronavirus disease 2019 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003252-24 | Sponsor Protocol Number: 53718678RSV2004 | Start Date*: 2018-01-16 | |||||||||||
Sponsor Name:Janssen Sciences Ireland UC | |||||||||||||
Full Title: A Pilot Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ- 53718678 at Two Dose Le... | |||||||||||||
Medical condition: Respiratory Syncytial Virus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Completed) SE (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003002-17 | Sponsor Protocol Number: 63623872FLZ2002 | Start Date*: 2015-11-17 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult and Elderly H... | |||||||||||||
Medical condition: Influenza A virus infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) BE (Completed) DE (Completed) NL (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001026-22 | Sponsor Protocol Number: 1813T0835 | Start Date*: 2021-03-05 |
Sponsor Name:Shionogi & Co., Ltd. | ||
Full Title: An Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Baloxavir Marboxil 2% Granules after Administration of a Single Dose to Otherwise Healthy Pediatric Patient... | ||
Medical condition: Influenza | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2009-015700-26 | Sponsor Protocol Number: AH1N1-483-09THL | Start Date*: 2009-10-16 | |||||||||||
Sponsor Name:National Institute for Health and Welfare | |||||||||||||
Full Title: Evaluation of a vaccination campaign with A(H1N1)v pandemic vaccines: a prospective cohort study. A(H1N1)v-pandemiarokotuskampanjan vaikutukset | |||||||||||||
Medical condition: Influenza caused by the new A(H1N1)v influenza virus ("swine influenza") | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021033-30 | Sponsor Protocol Number: H1N1-495-10THL | Start Date*: 2010-09-14 | |||||||||||
Sponsor Name:National Institute for Health and Welfare | |||||||||||||
Full Title: Evaluation of the effectiveness of vaccination with 2009 H1N1 vaccines during influenza season 2010-11 2009 H1N1-influenssarokotteiden tehokkuus influenssakaudella 2010-11 | |||||||||||||
Medical condition: Influenza caused by the 2009 H1N1 influenza virus ("swine influenza") | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005015-40 | Sponsor Protocol Number: IVER-303 | Start Date*: 2021-04-29 | |||||||||||
Sponsor Name:Chemo Research S.L. | |||||||||||||
Full Title: A multicentre, phase III, double-blind, randomised, parallel, placebo-controlled trial to assess efficacy and safety of early administration of Ivermectin during 3 consecutive days to prevent SARS ... | |||||||||||||
Medical condition: Coronavirus disease (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001467-82 | Sponsor Protocol Number: P020.051 | Start Date*: 2020-10-23 | ||||||||||||||||
Sponsor Name:Leiden University Medical Center | ||||||||||||||||||
Full Title: An Open-Label Study Evaluating Anti-Viral Effects of Voclosporin in SARS-CoV-2 Positive Kidney Transplant Recipients – the VOCOVID Study (COVID-19) | ||||||||||||||||||
Medical condition: SARS-CoV-2 infection in Kidney Transplant Recipients | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000455-39 | Sponsor Protocol Number: C21-109-09 | Start Date*: 2021-04-09 | |||||||||||
Sponsor Name:Pharma Holdings AS | |||||||||||||
Full Title: A double-blind, placebo-controlled, interventional parallel group study to evaluate the antiviral effect of a single nasal application of LTX-109 3% gel, in comparison to placebo gel, in subjects w... | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003642-93 | Sponsor Protocol Number: 53718678RSV2002 | Start Date*: 2018-12-05 | ||||||||||||||||
Sponsor Name:Janssen Sciences Ireland UC | ||||||||||||||||||
Full Title: A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Relationships of Different Doses o... | ||||||||||||||||||
Medical condition: Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus Infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) ES (Prematurely Ended) HU (Completed) SE (Completed) FR (Completed) DE (Prematurely Ended) PL (Completed) BG (Completed) Outside EU/EEA IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-005980-30 | Sponsor Protocol Number: 53718678RSV2008 | Start Date*: 2021-11-26 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rilematovir (JNJ-53718678) in Adult Outpatients with Respiratory Syncytial Virus (RSV) Infection... | |||||||||||||
Medical condition: Respiratory Syncytial Virus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) PL (Completed) HU (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002154-70 | Sponsor Protocol Number: CP40559 | Start Date*: 2019-10-24 | ||||||||||||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||||||||||||
Full Title: A MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF BALOXAVIR MARBOXIL IN OTHERWISE HEALTHY PEDIATRIC PATIENTS FROM BIRTH TO LESS THAN 1 YEAR WITH IN... | ||||||||||||||||||||||||||||
Medical condition: Influenza | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: PL (Completed) ES (Ongoing) FI (Completed) BG (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-000533-22 | Sponsor Protocol Number: VX-950-TiDP24-C216 | Start Date*: 2008-11-14 | |||||||||||
Sponsor Name:Tibotec BVBA | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, Phase III trial of 2 regimens of telaprevir (with and without delayed start) combined with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Cop... | |||||||||||||
Medical condition: Chronic genotype 1 Hepatitis C infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) SE (Completed) FR (Completed) AT (Completed) IT (Completed) GB (Completed) ES (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001918-25 | Sponsor Protocol Number: 111714 | Start Date*: 2009-01-15 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: An open Phase I/II study of immunization with the recMAGE-A3 + AS15 Antigen Specific Cancer Immunotherapeutic in association with dacarbazine in patients with MAGE-A3 positive unresectable and prog... | |||||||||||||
Medical condition: Patients with unresectable and progressive metastatic cutaneous melanoma, whose tumor expresses MAGE-A3. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000618-32 | Sponsor Protocol Number: GNC-501 | Start Date*: 2022-09-29 | ||||||||||||||||
Sponsor Name:GENEURO SA | ||||||||||||||||||
Full Title: Temelimab as a Disease Modifying Therapy in Patients with Neurological, Neuropsychological, and Psychiatric (=Neuropsychiatric) Symptoms in Post-COVID-19 or Postacute Sequelae of COVID-19 (PASC) Sy... | ||||||||||||||||||
Medical condition: Postacute Sequelae of COVID-19 (PASC) Syndrome | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003246-20 | Sponsor Protocol Number: ENX-CL-03-002 | Start Date*: 2021-11-02 | |||||||||||
Sponsor Name:Enlivex Therapeutics R&D, Ltd. | |||||||||||||
Full Title: A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients with Severe or Critical COVID-19 with Associated Acute Respi... | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001684-89 | Sponsor Protocol Number: RG_20-030 | Start Date*: 2020-05-05 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: CATALYST - A randomised phase II proof of principle multi-arm multi-stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection. | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001010-15 | Sponsor Protocol Number: REVC003 | Start Date*: 2019-10-24 | |||||||||||
Sponsor Name:ReViral Ltd. | |||||||||||||
Full Title: A Phase 2a Open-Label Study in Infants with REspiratory Syncytial VIRus Lower RespirAtory Tract Infection, Followed by a DoubLe-blind, Placebo-controlled Part, to Evaluate the Safety, Tolerability,... | |||||||||||||
Medical condition: Respiratory Syncytial Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022945-52 | Sponsor Protocol Number: ADVL0516 | Start Date*: 2012-01-26 | ||||||||||||||||
Sponsor Name:Children’s Oncology Group | ||||||||||||||||||
Full Title: A Phase 1 Study of BMS-354825 (Dasatinib) in Children with Recurrent/Refractory Solid Tumors or Imatinib Resistant Ph+ Leukemia. | ||||||||||||||||||
Medical condition: Refractory solid tumors Ph+ leukemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-005000-26 | Sponsor Protocol Number: 4658-us-201 | Start Date*: 2017-03-16 | |||||||||||
Sponsor Name:Sarepta Therapeutics, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Efficacy, Safety, Tolerability, and Pharmacokinetics Study of AVI-4658 (Eteplirsen), a Phosphorodiamidate Morpholino Oligomer, Administ... | |||||||||||||
Medical condition: Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
